T1d Exchange Inc

Programs: The first program of unitio was the creation of the t1d exchange. T1d exchange was born out of the need to improve outcomes for people with type 1 diabetes as fast as humanly possible. To help researchers overcome the many obstacles required to accelerate all aspects of drug and device development, the model offers easy access to aggregated clinical, biological, patient-reported outcomes and electronic health record data, all while fostering collaboration among patients, physicians, researchers and industry. To support its strategic initiatives, t1d exchange has built the following resources to drive the delivery of new treatments and better care faster to patients. (1) patient-centered research is supported by our online community, glu, amplifies the collective voice of people living with type 1 diabetes. Our more than 20,000 t1d patients, caregivers, and supporters can connect, offer peer-to-peer support, access educational resources, and participate directly in surveys, discussions, and research that may ultimately benefit their own health. This real-world data adds fresh new perspectives to traditional methods of inquiry. Our clinic registry features well-characterized data from 32,000 enrolled patients from our clinic network. We continue to expand our reach into the t1d community to grow our circles of engaged participants. (2) collaborative science is supported by: the t1d exchange biobank, which acts as a catalyst for the exchange of knowledge and collaboration. A world-class resource for innovative research, the biobank contains thousands of biological specimens and patient data to help better understand causes of type 1 diabetes and responses to therapy. (3) improving quality care is supported by: our quality improvement (qi) initiative where t1d exchange aims to develop, test, and implement an integrated clinical care and research system in type 1 diabetes. (4) accelerating innovation is supported by: the t1d exchange diabetes innovation challenge, a competition designed to present the most promising innovations in type 1 diabetes to our network of funders, investors, and partners from academia and industry. Participating organizations can win awards for their innovations and make connections that may help them advance to the next stage of development. Since our founding in 2010, the t1d exchange has grown into a leading type 1 diabetes resource in the research, medical, and healthcare innovation communities. We've completed several large-scale clinical studies - and helped accelerate a potentially game-changing treatment for severe hypoglycemia. Our patient-centered research findings have significantly grown the knowledge base about life with type 1 diabetes and at times even challenged conventional schools of thought; resulting in more informed research, more meaningful studies on unmet needs, and improved care. Our work continues to evolve as we grow our patient-centered cohorts, expand our resources, and develop new and impactful ways to collaborate across the t1d ecosystem. Here are some of recent highlights of our work:in 2017, we enabled three innovative companies to receive financial aid and in-kind support to advance the development of their novel products. Our patient-centered research data helped to secure approval to use cgm (continuous glucose monitoring) systems without confirmatory reading from blood glucose monitoring; supporting fda's decision in late 2016 to expand the indication for the dexcom g5 cgm systems and removing the key obstacle in early 2017 that secured cgm coverage from medicare/medicaid. State workers with type 1 diabetes in washington are receiving more blood glucose strips per day as a result of our data. Our online community, glu, has also been used to successfully rescue two industry studies and one nih funded study that could not meet initial study recruitment goals. A large t1d exchange study confirmed the presence of c-peptide in patients across a wide age spectrum. This decreases the risks of misdiagnosing type 1 as the more common type 2 diabetes, and may help improve treatments to control glucose levels. What's more, the study supports access to insulin pumps for as many as 10% of type 1 diabetes patients overall and 20% of those diagnosed as adults, who many not have met medicare, medicare, medicaid, and many private insurer's criteria for an insulin pump. T1d exchange is widely recognized in the global medical community and have given well over 100 presentations at leading medical, scientific, and advocacy events across the globe and published nearly 50 manuscripts in key peer-reviewed journals. In addition these groundbreaking research studies, the t1d exchange continue to follow our registry cohort and provide ongoing support to our 30,000+ lives of patients, caregivers and industry partners through numerous articles within glu and the national diabetes community; participation and presentation at national conferences such as ada; and national and local community events such as the t1d exchange annual meeting.